Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.66 USD | +1.22% | +9.21% | -12.17% |
Mar. 25 | HC Wainwright Cuts Price Target on Rockwell Medical to $9 From $11, Keeps Buy Rating | MT |
Mar. 21 | Transcript : Rockwell Medical, Inc., Q4 2023 Earnings Call, Mar 21, 2024 |
Financials (USD)
Sales 2024 * | 88.97M | Sales 2025 * | 101M | Capitalization | 48.7M |
---|---|---|---|---|---|
Net income 2024 * | -2M | Net income 2025 * | 1M | EV / Sales 2024 * | 0.55 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.48 x |
P/E ratio 2024 * |
-16.6
x | P/E ratio 2025 * |
27.7
x | Employees | 237 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97% |
Latest transcript on Rockwell Medical, Inc.
1 day | +1.22% | ||
1 week | +9.21% | ||
Current month | +17.73% | ||
1 month | +22.06% | ||
3 months | -14.87% | ||
6 months | -17.00% | ||
Current year | -12.17% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Strobeck
CEO | Chief Executive Officer | 53 | 22-06-30 |
Jesse Neri
DFI | Director of Finance/CFO | - | 23-10-17 |
Marc Hoffman
CTO | Chief Tech/Sci/R&D Officer | 63 | 19-11-19 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Cooper
BRD | Director/Board Member | 65 | 17-09-06 |
Allen Nissenson
BRD | Director/Board Member | 77 | 20-06-10 |
Mark Strobeck
CEO | Chief Executive Officer | 53 | 22-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1.66 | +1.22% | 349,810 |
24-03-27 | 1.64 | -0.61% | 254,190 |
24-03-26 | 1.65 | +1.85% | 432,703 |
24-03-25 | 1.62 | -5.26% | 310,515 |
24-03-22 | 1.71 | +12.50% | 643,949 |
Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.17% | 48.7M | |
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+2.95% | 212B | |
+0.74% | 209B | |
-6.05% | 205B | |
-3.61% | 157B |